Skandinaviska Enskilda Banken AB publ Purchases 1,028,921 Shares of ImmunityBio, Inc. $IBRX

Skandinaviska Enskilda Banken AB publ lifted its holdings in ImmunityBio, Inc. (NASDAQ:IBRX) by 347.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,324,871 shares of the company’s stock after purchasing an additional 1,028,921 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in ImmunityBio were worth $3,246,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in IBRX. Slow Capital Inc. bought a new stake in ImmunityBio during the 3rd quarter valued at approximately $25,000. Envision Financial Planning LLC acquired a new position in shares of ImmunityBio during the second quarter worth approximately $28,000. Summit X LLC acquired a new position in shares of ImmunityBio during the second quarter worth approximately $28,000. Diversify Advisory Services LLC bought a new stake in shares of ImmunityBio in the second quarter valued at approximately $27,000. Finally, Truist Financial Corp bought a new stake in ImmunityBio in the 3rd quarter valued at $27,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

Insider Buying and Selling

In other news, Director Christobel Selecky sold 50,000 shares of the stock in a transaction on Friday, January 16th. The stock was sold at an average price of $5.00, for a total value of $250,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Barry J. Simon sold 151,967 shares of ImmunityBio stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the transaction, the director directly owned 3,091,604 shares in the company, valued at $22,259,548.80. The trade was a 4.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 226,967 shares of company stock worth $1,531,912 over the last quarter. 69.48% of the stock is owned by company insiders.

ImmunityBio Price Performance

ImmunityBio stock opened at $8.70 on Friday. The firm has a market capitalization of $8.57 billion, a P/E ratio of -21.22 and a beta of 0.16. The stock has a fifty day moving average price of $4.48 and a two-hundred day moving average price of $3.11. ImmunityBio, Inc. has a 52-week low of $1.83 and a 52-week high of $9.25.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on IBRX shares. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. BTIG Research lifted their target price on ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. HC Wainwright upped their price target on ImmunityBio from $8.00 to $10.00 and gave the company a “buy” rating in a report on Monday, January 26th. D. Boral Capital reiterated a “buy” rating and issued a $24.00 price objective on shares of ImmunityBio in a research report on Tuesday. Finally, Piper Sandler lifted their price objective on ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, ImmunityBio has an average rating of “Moderate Buy” and a consensus price target of $11.80.

ImmunityBio News Summary

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: European conditional approval and EU commercialization push — the European Commission granted conditional marketing authorization for ANKTIVA® in combination with BCG for BCG‑unresponsive NMIBC CIS, and ImmunityBio is opening an Irish subsidiary and signing distribution deals (Accord) to support the EU launch, which meaningfully expands addressable market and revenue runway. ImmunityBio Expands Access to ANKTIVA® in EU (BusinessWire)
• Positive Sentiment: Regional commercial expansion — ImmunityBio struck a partnership with Biopharma and Cigalah Healthcare to launch ANKTIVA® in Saudi Arabia and the broader MENA region, giving the drug local distribution partners and accelerating market entry in a sizeable oncology market. ImmunityBio Partners to Launch ANKTIVA in Saudi Arabia (BusinessWire)
• Positive Sentiment: Technical momentum — the stock is showing strong technicals (reported “golden cross” and trading well above the 200‑day average), reinforcing momentum traders and institutional interest. ImmunityBio Holds Golden Cross (Benzinga)
• Neutral Sentiment: Chairman commentary and publicity — public comments linking diplomatic efforts to commercial success have generated headlines and may sustain retail interest, but they are narrative-driven rather than new financial data. Chairman Comments on Diplomacy (MSN)
• Neutral Sentiment: Corporate finance/clinical updates referenced in coverage — some articles note follow‑up clinical programs and past convertible‑note activity; these are worth monitoring for dilution or R&D progress but contain no immediate financial details. Clinical/Convertible Note Context (MSN)
• Negative Sentiment: Investor litigation investigation — Pomerantz LLP announced an investigation into ImmunityBio on behalf of investors, which introduces legal and reputational risk that could pressure the stock if it leads to claims or disclosures. Pomerantz Investigates (PR Newswire)

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.